FOLH1 and prostate cancer: As advanced imaging techniques for prostate cancer become more common [i.e. prostate-specific membrane antigen-positron emission tomography (PSMA-PET), multi-parametric magnetic resonance imaging (mpMRI)] and with the emergence of new therapeutic approaches (improvements in ablative therapies and surgical techniques), there is renewed interest in local therapies with deferred ADT treatment [9-11].